Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention
Abstract Background The CYP2C19 nonfunctional genotype reduces clopidogrel effectiveness after percutaneous coronary intervention (PCI). Following clinical implementation of CYP2C19 genotyping at University Florida (UF) Health Shands Hospital in 2012, where genotype results are available approximate...
Main Authors: | Larisa H. Cavallari, Francesco Franchi, Fabiana Rollini, Latonya Been, Andrea Rivas, Malhar Agarwal, D. Max Smith, Kimberly Newsom, Yan Gong, Amanda R. Elsey, Petr Starostik, Julie A. Johnson, Dominick J. Angiolillo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-04-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12967-018-1469-8 |
Similar Items
-
Oral antiplatelet therapy and platelet inhibition: An experience from a tertiary care center
by: Jamshed J. Dalal, et al.
Published: (2016-09-01) -
Impact of Routine Platelet Reactivity Testing with VerifyNow Assay on Antiplatelet Choice After Percutaneous Coronary Intervention
by: Mshelbwala FS, et al.
Published: (2020-04-01) -
Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?
by: T. M. Uskach, et al.
Published: (2020-12-01) -
Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01) -
Ticagrelor
by: Gianluca Airoldi, et al.
Published: (2013-03-01)